Spyre Therapeutics (SYRE) Change in Accured Expenses (2015 - 2026)

Spyre Therapeutics has reported Change in Accured Expenses for 12 years, with the latest figure at $3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 160.9% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (up 1831.96% YoY), and the FY2025 full-year result was -$764000.0, down 105.23% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $3.7 million, up from $3.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $14.9 million in Q4 2024, with the low at -$15.8 million in Q2 2024.
• Historically, Change in Accured Expenses has averaged $692000.0 across 5 years, with a median of $450000.0 in 2022.
• The largest YoY upside for Change in Accured Expenses was 1768.46% in 2024 against a maximum downside of 849.0% in 2024.
• Spyre Therapeutics' Change in Accured Expenses stood at $450000.0 in 2022, then tumbled by 298.0% to -$891000.0 in 2023, then surged by 1768.46% to $14.9 million in 2024, then tumbled by 78.99% to $3.1 million in 2025, then rose by 16.93% to $3.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $3.7 million (Q1 2026), $3.1 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.